Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A

Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A

SSSE:600479
10.20
CNY
-0.08
(-0.78%)
0.84EPS
16.80P/E
6.10BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.39
6
6.38
6.85
7.6
7.95
8.42
8.67
8.75
9.4
8.99
8.78
8.42
7.76
Basic EPS, GAAP
0.34
0.29
0.24
0.36
0.5
0.61
0.7
0.71
0.72
0.71
0.76
0.56
0.66
0.74
Free Cash Flow per Basic Share
0.15
0.32
-0.04
0.14
0.55
0.81
0.27
1.06
0.99
1.63
0.94
0.85
0.83
- -
Dividend per Share
0.22
0.17
0.17
0.13
0.17
0.25
0.4
0.5
1.03
0.58
0.35
0.37
0.35
- -
Book Value per Share
2.76
3.07
3.93
4.17
4.49
4.9
5.2
5.42
5.14
5.16
5.57
5.81
6.15
6.3
Tangible Book Value per Share
2.03
2.35
3.28
3.52
3.88
4.18
4.56
4.87
4.58
4.61
4.98
5.22
5.54
5.63
Basic Weighted Avg Shares
366
366
383
418
419
418
419
419
418
428
423
414
431
483
Sales/Revenue/Turnover
1,973
2,194
2,447
2,865
3,183
3,329
3,525
3,627
3,664
4,026
3,798
3,630
3,629
3,751
Operating Margin (%)
7.89
5.87
3.77
6.28
8.44
9.11
10.18
10.24
10.11
10.55
11.1
8.29
10.41
11.62
Depreciation Expense
48
48
50
50
63
62
61
61
86
96
104
100
108
- -
Net Income, GAAP
124
105
93
149
208
255
294
297
302
303
320
231
286
357
Effective Tax Rate (%)
15.75
16.18
19.4
16
13.95
14.12
18.06
15.16
13.54
13.16
14.21
9.75
13.66
14.84
Profit Margin (%)
6.27
4.79
3.8
5.22
6.53
7.67
8.35
8.19
8.24
7.51
8.44
6.36
7.89
9.51
Working Capital
487
685
1,266
1,296
1,495
1,643
1,854
1,781
1,689
1,816
1,973
1,396
672
700
LT Debt
5
32
54
47
37
27
21
62
60
45
38
26
29
24
Total Equity
1,204
1,386
1,964
2,084
2,241
2,452
2,630
2,762
2,700
2,817
3,027
3,139
3,350
3,436
Return on Invested Capital (%)
9.97
7.69
4.3
7.78
11.37
11.92
13.57
12.66
12.84
13.16
12.84
9.4
11.34
11.89
Return on Capital (%)
9.87
7.04
5.88
6.16
7.76
8.77
9.23
8.37
7.93
7.59
8.13
5.04
5.92
9.09
Return on Common Equity (%)
12.54
9.87
6.72
8.81
11.47
13
13.92
13.37
13.68
13.85
13.91
9.51
10.43
12.87

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
35
130
105
LT Borrowings
- -
- -
- -
LT Finance Leases
27
26
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
492
492
492
Market Capitalization
5,286
4,578
6,103

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,333
2,232
2,324
Cash, Cash Equivalents & STI
666
708
707
Accounts Receivable, Net
397
397
367
Inventories
487
491
518
Total Current Liabilities
1,579
1,537
1,625
Payables & Accruals
- -
- -
- -
ST Debt
35
130
105
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.53%
3.99%
6.72%
Free Cash Flow
11.44%
1.68%
1.32%
Net Income, GAAP
14.27%
0.77%
24.07%
Sales/Revenue/Turnover
4.23%
0.16%
-0.03%
Total Cash Common Dividend
17.01%
5.16%
-0.09%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,001
924
790
915
3,630
2025
1,005
813
- -
911
3,629
2026
970
948
922
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.17
0.12
0.15
0.56
2025
0.13
0.18
- -
0.22
0.66
2026
0.15
0.22
0.16
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.36
0.01
-0.01
0.37
2025
- -
- -
- -
- -
0.35
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zhi Yong Chen
Full Time Employees
5,041
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 801 Zhuzhou Avenue Zhuzhou HU China 412007
IPO Date
Mar 12, 2004
Website
qjyy.com
Business
ZhuZhou QianJin Pharmaceutical Co., Ltd. (600479.SS) researches, develops, produces and sells Chinese patent medicines, chemical medicines and feminine hygiene products in China; engages in the wholesale and retail of pharmaceuticals; and operates ancillary businesses including sales of health care products, cosmetics, disinfectants, daily necessities and equity investments. Core products encompass gynecological Qianjin tablets and capsules for women's health; blood supplementation pills and granules; valsartan capsules and enalapril maleate tablets for cardiovascular treatment; difenidol hydrochloride tablets; silybin glucamine tablets; entecavir dispersible tablets for antiviral use; finasteride tablets; ammonium benzenesulfonate tablets; and specialized gynecological wipes, spanning gynecology, pediatrics, circulatory, endocrine, digestive, nervous system and other therapeutic categories in tablets, granules and capsules. Founded in 1966 as the predecessor Zhuzhou Pharmaceutical Company's Proprietary Chinese Medicine Processing Plant, it underwent shareholding reform in 1993, listed on the Shanghai Stock Exchange in 2004 and maintains headquarters at No. 801 Zhuzhou Avenue, Tianyuan District, Zhuzhou, Hunan province, China, with primary operations across the country. In October 2025, the company completes the acquisition of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. for approximately CNY 620 million in cash and shares to bolster its pharmaceutical portfolio.